Introduction. Tension-free hernia repair has been regarded as a gold standard treatment for selected inguinal hernias, but the use of prosthetic mesh in acute incarcerated inguinal hernias is controversial. Our study focused on evaluating the safety and efficacy of the prosthetic mesh repair for emergency cases. Methods. Patients with acute incarcerated inguinal hernias who underwent emergency prosthetic mesh repair during 2009 to 2014 at our department were included. Patient characteristics, operative approaches and results, and complications were retrospectively analyzed. Results. A total of 167 patients were included in our study. One hundred and twenty-two patients underwent open surgery while the remaining 45 patients underwent transabdominal preperitoneal laparoscopic approach. The hernia was indirect inguinal in 133 patients (79.6%), direct inguinal in 15 patients (9.0%), and femoral in 19 patients (11.4%). The overall wound infection rate of these patients was 3%. Nonviable intestinal resection was performed in 25 patients (8.4%), only 2 of whom underwent wound infection. Another 3 patients who developed wound infection had viable hernia content. There was no mesh-related infection. There was no statistically significant difference in wound infection rates between patients with viable hernia contents and those with nonviable contents (P < .05). Conclusion. The use of the prosthetic mesh in the treatment of acute incarcerated inguinal hernia is safe and effective. Nonviable intestinal resection cannot be regarded as a contradiction of the mesh repair.
Background and Objectives: the total neoadjuvant chemoradiotherapy (TNT) includes different strategies, but the most appropriate model remains uncertain. The purpose of this retrospectively study was to evaluate the safety and pathological response in the consolidation chemotherapy model. Methods: patients with cT3/T4 or TxN + M0 rectal cancer that were receiving neoadjuvant chemoradiotherapy (CRT) (50 Gy with oral capecitabine)/TNT (CRT followed by three cycles of CAPOX) during September 2017 to September 2019 in our department were included. All of the patients were recommended to receive radical surgery. Results: a total of 197 patients were included. Eighty-one patients received CRT, while one hundred and sixteen patients received TNT. Nine patients did not undergo surgery because of the distant metastases (one patient (1.2%) in CRT group, two patients (1.7%) in TNT group) or a refusal of resection (two patients in CRT group, four patients in TNT group). The pathological complete response (pCR) rate was 32.7% in TNT compared with 12.8% in CRT (p = 0.002). There was no statistically significant difference in grade 3 acute toxicities of neoadjuvant treatment and surgical complications between the two groups. Conclusions: the consolidation chemotherapy model is safe for patients with locally advanced rectal cancer and it has a high pCR rate. The long-term follow-up is necessary to be evaluated in a future prospective, randomized trial.
27 June 2025 in World Journal of Gastrointestinal Surgery
BACKGROUND Self-expandable metallic stent (SEMS) placement is a common intervention for obstructive left-sided colon cancer. However, the long-term prognosis post-SEMS placement remains debated. Mechanical compression within the tumor caused by SEMS may induce vascular compression, leading to tissue ischemia and hypoxia. These alterations in the tumor microenvironment could affect patient prognosis. AIM To assess the influence of glucose transporter-1 (GLUT-1) and Ki-67 expression in obstructive colon cancer tissues pre and post SEMS placement on patient prognosis. METHODS A retrospective analysis was conducted on clinical and pathological data from 71 patients with obstructive colon cancer who underwent SEMS placement followed by surgery. Paired colon cancer tissue samples were collected from each patient pre and post SEMS placement. Immunohistochemical techniques were employed to evaluate GLUT-1 and Ki-67 expression in the specimens. RESULTS The high expression rates of GLUT-1 in the samples obtained before and after SEMS placement were 14.1% and 43.7%, respectively (P < 0.001). GLUT-1 expression was associated with vascular invasion post-SEMS placement (P = 0.03). Ki-67 expression showed no significant difference pre and post SEMS placement and was unrelated to clinical pathological characteristics (all P > 0.05). The high expression rates of GLUT-1 in the samples obtained before and after SEMS placement were associated with worse recurrence-free interval (pre-SEMS: 40.0% vs 72.3%, P = 0.026; post-SEMS: 45.5% vs 85.7%, P = 0.001). Cox regression analysis revealed that both pre-SEMS placement (HR = 3.490, 95%CI: 1.165-10.453, P = 0.026) and post-SEMS placement (HR = 4.335, 95%CI: 1.539-12.214, P = 0.006) GLUT-1 expression were adverse prognostic factors for patients. CONCLUSION Though the precise impact of stent placement on the mechanical compression and biological behavior of tumors is not fully understood, our study found an increase in GLUT-1 expression in tumor tissues after SEMS placement. Tumor GLUT-1 serves as a prognostic biomarker for the survival of patients with obstructive colon cancer treated with SEMS placement.
Background: To improve the prognosis of patients with obstructive colon cancer, performing neoadjuvant chemotherapy after self-expanding metallic stent (SEMS) placement followed by elective surgery is currently one of the treatment methods for obstructive colon cancer. However, the oncological risks of this treatment approach are currently unclear. To evaluate the oncological risks of this treatment model by detecting changes in circulating cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA) during the stent placement combined with neoadjuvant chemotherapy process.Methods: From January to December 2023, 10 patients with obstructive colon cancer who received neoadjuvant chemotherapy after SEMS placement, followed by surgical treatment, were included in this study. Blood samples were collected one day before stent placement, 3 days after stent placement, one day before surgery, and one day after surgery. cfDNA and ctDNA in the blood were detected and analyzed.Results: The stent placement success rate was 100%, with no cases of perforation, displacement, or re-obstruction, and no perioperative deaths. After neoadjuvant chemotherapy, peripheral ctDNA decreased compared to before stent placement. There were no statistically significant differences in cfDNA and ctDNA changes at the four time points during the treatment process.Conclusions: This study did not find an increase in ctDNA after stent placement combined with chemotherapy, suggesting that the model of stent placement combined with neoadjuvant chemotherapy for obstructive colon cancer may be a safe and reliable therapy.